Showing 2381-2390 of 3223 results for "".
- Physicians, Patients Overwhelmingly Support FDA Distinct Biologic Naming Plan, Suffixes for New Productshttps://modernod.com/news/physicians-patients-overwhelmingly-support-fda-distinct-biologic-naming-plan-suffixes-for-new-products/2476581/US physicians and patient advocacy organizations expressed their support for the FDA’s suffix-based naming system for biologic medicines and biosimilars, according to The Alliance for Safe Biologic Medicines. Comments were electronically submitted last week to the agency. Biologic me
- Eyepromise Introduces Screen Shield Teen All-Natural Eye Vitamin for Screen Time Protectionhttps://modernod.com/news/eyepromise-introduces-screen-shield-teen-all-natural-eye-vitamin-for-screen-time-protection/2476410/EyePromise announced the introduction of Screen Shield Teen to its premium EyePromise eye vitamin line. Screen Shield Teen is an ocular nutrition supplement specially formulated to preserve and support visual comfort and wellness for children ages 4-17. The vast majority of teens in the Un
- Low Birth Weight Tied to Altered Eye Anatomy in Adulthoodhttps://modernod.com/news/low-birth-weight-tied-to-altered-eye-anatomy-in-adulthood/2476361/Low birth weight appears to increase the chances of having thinner central cornea and other ocular anomalies in adulthood, according to a new study from Germany, as reported by Reuters. “With our data we provide new insight in
- Bausch + Lomb Acquires Eton Pharmaceuticals’ EM-100 Investigational OTC Eye Drop For Allergic Conjunctivitishttps://modernod.com/news/bausch-health-acquires-eton-pharmaceuticals-em-100-investigational-eye-drop-for-the-treatment-of-itchy-eyes-associated-with-allergies/2476282/Bausch Health Companies’ subsidiary Bausch + Lomb has acquired the US rights to Eton Pharmaceuticals’ investigational eye drop EM-100. If approved, the eye drop will be the first over-the-counter preservative-free formulation eye drop for the treatment of ocular itching associated wit
- EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-yutiq/2476328/EyePoint Pharmaceuticals announced the US commercially launch of Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in
- University of Alberta Scientists Pinpoint a Cause of Pigmentary Glaucomahttps://modernod.com/news/university-of-alberta-scientists-pinpoint-a-cause-of-pigmentary-glaucoma/2476337/An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition. “People who traditionally we wouldn’t think of having glaucoma—young males in their 20s and 30s—are at particular risk
- Compulink Showcases SMART Ophthalmology EHR Solution at Hawaiian Eye 2019https://modernod.com/news/compulink-showcases-smart-ophthalmology-ehr-solution-at-hawaiian-eye-2019/2476177/Compulink Healthcare Solutions will demonstrate its ophthalmology-specific system, Ophthalmology Advantage at Hawaiian Eye. Ophthalmology Advantage uses AI technology and real-time data from the clinic to completely automate tasks such as billing, along with eliminating steps to improve pa
- MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF for Ophthalmic Diseaseshttps://modernod.com/news/manf-therapeutics-receives-notice-of-allowance-from-us-patent-trademark-office-covering-the-use-of-manf-or-cdnf-for-ophthalmic-diseases/2476184/MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, is in preclinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases. On Tuesday, the
- RetinaLyze Receives Funding to Detect Diseases Such as Alzheimer’s Using AIhttps://modernod.com/news/retinalyze-receives-funding-to-detect-diseases-such-as-alzheimers-using-ai/2479612/RetinaLyze System A/S (Ltd.), a Denmark-based medical technology company that specializes in retinal imaging screening software, has received funding from The European Regional Development Fund (ERDF) and Central Denmark Region. The funding will be used to explore and develop novel AI-based solut
- SemaThera Board Names Garth Cumberlidge as President & CEOhttps://modernod.com/news/semathera-board-names-garth-cumberlidge-as-president-ceo/2479705/SemaThera announced that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retin